Myelodysplastic syndrome with isolated del(5q) (5q-syndrome)
Patients with a myelodysplastic/myeloproliferative neoplasm
Myelodysplastic syndrome
Any evidence of myelodysplastic syndrome or marrow chromosomal changes suggesting myelodysplasia (-7, -5 etc)
Bone marrow examination revealing myelodysplastic syndrome or megakaryocyte underproduction for patients with a platelet count < 50,000/uL
No prior history of myelodysplastic syndrome or other myeloid malignancy
Prior treatment of myelodysplastic syndrome or myeloproliferative neoplasm with hypomethylating agent acceptable
Myelodysplastic syndrome with multi-lineage dysplasia with or without chromosomal abnormalities
Myelodysplastic/myeloproliferative disease\r\n* Juvenile myelomonocytic leukemia (JMML)\r\n* Myelodysplastic syndrome and/or pre-leukemia at any stage
Myelodysplastic syndrome
Known history of myelodysplastic syndrome/leukemia at any time
Criteria 5 Myelodysplastic syndrome
Known presence of intermediate- or high-grade myelodysplastic syndrome.
Diagnosis of myelodysplastic syndrome.
History of myelodysplastic syndrome or organ transplantation
Myelodysplastic syndromes
For Cohort A: Has myelodysplastic syndrome
Presence of known intermediate- or high-grade myelodysplastic syndrome
History of myelodysplastic syndrome or solid organ transplantation
Subject who has any histopathologic finding consistent with myelodysplastic syndrome on bone marrow studies.
Myelodysplastic syndrome
Patients must not have been diagnosed with myelodysplastic syndrome or with any malignancy other than neuroblastoma
Myelodysplastic syndrome
Patients who have a history of myelodysplastic syndrome
Diagnosis of Myelodysplastic Syndrome.
Prior treatment of myelodysplastic syndrome or myeloproliferative neoplasm acceptable
Myelodysplastic syndrome with fibrosis (MF 3)
Known presence of myelodysplastic syndrome
Known presence of myelodysplastic syndrome
Known presence of myelodysplastic syndrome
Myelodysplastic syndrome\r\n* =< 55 years of age and >= 10% blasts, not responsive to hypomethylating agents and/or conventional therapy
Patients with low- and Int-1-risk myelodysplastic syndrome
Patients with myelodysplastic syndrome
Patients with myelodysplastic syndrome
Patients with myelodysplastic syndrome.
Known myelodysplastic syndrome
Known myelodysplastic syndrome.
Phase I: Hematologic malignancy diagnosis including any subset of myeloma, lymphoma, leukemia, or myelodysplastic syndrome
Phase II: Hematologic malignancy diagnosis including any subset of lymphoma, leukemia, or myelodysplastic syndrome
Known relapsed acute leukemia or myelodysplastic syndrome
Current Myelodysplastic syndrome only subjects
Subjects with a history of myelodysplastic syndrome
Diagnosed with hematological malignancy or marrow failure syndrome such as but not limited to: aplastic anemia, myelodysplastic syndrome or leukemia
Subjects with treatment-related myelodysplastic syndrome.
Myelodysplastic Syndrome
Current or prior history of myelodysplastic syndrome, leukemia or clinically significant (as per Investigator judgment) bone marrow failure.
Prior intensive chemotherapy or stem cell transplantation for the treatment of myelodysplastic syndrome
